Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucia Carril-Ajuria

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Bulletin Du Cancer|June 30, 2024
Une nouvelle place pour les biomarqueurs circulants dans le cancer du rein en 2024 ?Ronan Flippot, Lucia Carril-Ajuria
Journal of Medical Case Reports|September 5, 2018
An unsuspected complication with immune checkpoint blockade: a case reportLucia Carril-Ajuria, Elisabeth Jiménez-Aguilar, Carlos Gómez-Martín, et al.
Journal of Cancer Research and Clinical Oncology|January 22, 2022
Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive reviewLucia Carril-Ajuria, Maria Cruz Martin-Soberón, Guillermo de Velasco, et al.
Cancer Treatment Reviews|June 22, 2021
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good newsFrancisco Zambrana, Lucia Carril-Ajuria, Alfonso Gómez de Liaño, et al.
Clinical Genitourinary Cancer|November 15, 2020
Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 TherapyLucia Carril-Ajuria, David Lora, Alberto Carretero-González, et al.
Oncotarget|December 14, 2020
A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trialGuillermo de Velasco, Lucia Carril-Ajuria, Felix Guerrero-Ramos, et al.
Clinical Genitourinary Cancer|October 24, 2021
Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell CarcinomaLuigi Cerbone, Vincenzo Di Nunno, Lucia Carril Ajuria, et al.
Journal for Immunotherapy of Cancer|April 17, 2024
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumorsRonan Flippot, Marcus Teixeira, Macarena Rey-Cardenas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2025
High circulating IL-6/IL-8 is associated with intratumoral myeloid contexture and poor outcomes in advanced renal cell carcinoma patients treated with PD-1 blockadeLucia Carril-Ajuria, Ronan Flippot, Marie Naigeon, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric studyEdwige Baudry, Natacha Naoun, Edouard Auclin, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Bulletin Du Cancer|June 30, 2024
Une nouvelle place pour les biomarqueurs circulants dans le cancer du rein en 2024 ?Ronan Flippot, Lucia Carril-Ajuria
Journal of Medical Case Reports|September 5, 2018
An unsuspected complication with immune checkpoint blockade: a case reportLucia Carril-Ajuria, Elisabeth Jiménez-Aguilar, Carlos Gómez-Martín, et al.
Journal of Cancer Research and Clinical Oncology|January 22, 2022
Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive reviewLucia Carril-Ajuria, Maria Cruz Martin-Soberón, Guillermo de Velasco, et al.
Cancer Treatment Reviews|June 22, 2021
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good newsFrancisco Zambrana, Lucia Carril-Ajuria, Alfonso Gómez de Liaño, et al.
Clinical Genitourinary Cancer|November 15, 2020
Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 TherapyLucia Carril-Ajuria, David Lora, Alberto Carretero-González, et al.
Oncotarget|December 14, 2020
A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trialGuillermo de Velasco, Lucia Carril-Ajuria, Felix Guerrero-Ramos, et al.
Clinical Genitourinary Cancer|October 24, 2021
Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell CarcinomaLuigi Cerbone, Vincenzo Di Nunno, Lucia Carril Ajuria, et al.
Journal for Immunotherapy of Cancer|April 17, 2024
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumorsRonan Flippot, Marcus Teixeira, Macarena Rey-Cardenas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2025
High circulating IL-6/IL-8 is associated with intratumoral myeloid contexture and poor outcomes in advanced renal cell carcinoma patients treated with PD-1 blockadeLucia Carril-Ajuria, Ronan Flippot, Marie Naigeon, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric studyEdwige Baudry, Natacha Naoun, Edouard Auclin, et al.
Pageof 3